PubMed Health⌕ Search

Biomedical subjects

G Plicchi

Publications and source records attributed to G Plicchi.

At least 19 recordsLinked to original sources
PubMed2006

A new hermetic antenna for wireless transmission systems of implantable medical devices.

In implantable medical devices (IMDs), the need of telemetry systems able to provide wireless bidirectional communication to interrogate and remotely program the device, as well as to monitor the physiological status of the patient, is growing. The object of the present study was to evaluate a new hermetic antenna for wireless short-range transmission system for IMDs which would assure reliable long-term functioning due to the high level of hermeticity of antenna's housing that limits the influence of body tissue environment on transmitted signals. Experimental tests were conducted on three different prototypes to evaluate the most efficient antenna configuration for transmission both in the air and through a mixture simulating the human thorax. Further tests were performed to assess the influence of electro-catheters connected to IMDs on transmitted signals. Results showed that the hermetic antenna guarantees a good wireless transmission both in the air and through the human thorax simulator. The results also show that the presence of an electro-catheter can influence the effective radiated power (ERP) transmitted depending on its position in relation to the telemetric circuitry. Both a controlled increase of the ERP without exceeding the limits imposed by rules and the optimization of the tuning between the antenna and the transmitter can assure a reliable short-range transmission (several meters) using the new hermetic antenna proposed.

Equipment Design↗
PubMed2002

PEA I and PEA II based implantable haemodynamic monitor: pre clinical studies in sheep.

AIMS: The aims of this study were first, to demonstrate that Peak Endocardial Acceleration during isovolumic systole (PEA I) is related to positive peak LVdP/dt, while Peak Endocardial Acceleration during isovolumic relaxation time (PEA II) is related to aortic diastolic pressure (ADP) and to negative peak LVdP/dt; and second, to test if the simultaneous recording of PEA I and PEA II offers a new chance to monitor indexes of LV systolic and diastolic function. METHODS: An implantable haemodynamic monitor, based on PEA I and PEA II measurements via a microaccelerometer sensor located in the tip of a pacing lead, screwed into the right ventricle, was tested in nine sheep at baseline and during acute haemodynamic interventions: nitrate (0.1 mg/ kg), metaraminol (0.15 mg/kg), dobutamine (5 microg/kg) infusion. ADP, positive and negative peak LVdP/dt were simultaneously recorded by an aortic and left ventricular Millar catheter. RESULTS: PEA I changes were significantly related to positive peak LVdP/dt changes during dobutamine induced inotropic changes (r = 0.83, P < 0.001). PEA II changes were significantly related to both ADP (r = 0.91, P < 0.001) and negative peak LVdP/dt changes (r = 0.92, P < 0.001) during nitrate induced hypotension and metaraminol induced hypertension. CONCLUSION: The simultaneous recording of PEA I and PEA II with an implantable system offers a new chance to monitor indexes of LV systolic and diastolic function.

Animals↗
PubMed2001

Operator independent left ventricular function monitoring during pharmacological stress echo with the new peak transcutaneous acceleration signal.

BACKGROUND: As the myocardium contracts isometrically, it generates vibrations that can be measured with an accelerometer. The vibration peak, peak endocardial acceleration (PEA), is an index of contractility. OBJECTIVE: To evaluate the feasibility of PEA measured by the cutaneous precordial application of the accelerometer sensor; and to assess the usefulness of PEA monitoring during pharmacological stress echocardiography. DESIGN: Feasibility study. SETTING: Stress echo laboratory. PATIENTS: 34 consecutive patients underwent pharmacological stress (26 with dipyridamole; 8 with dobutamine) and PEA monitoring simultaneously. INTERVENTIONS: A microaccelerometer was positioned in the precordial region and PEA was recorded. Dipyridamole was infused up to 0.84 mg/kg in 10 minutes, and dobutamine up to 40 microg/kg/min in 15 minutes. RESULTS: A consistent PEA signal was obtained in all patients. Overall mean (SD) baseline PEA was 0.26 (0.15) g (g = 9.8 m/s(2)), increasing to 0.5 (0.36) g at peak stress (+0.24 g, 95% confidence interval (CI) 0.14 to 0.34 g; p < 0.01). PEA increased from 0.26 (0.16) to 0.37 (0.25) g in the dipyridamole group (+0.11 g, 95% CI 0.08 to 0.16 g; p < 0.01), and from 0.29 (0.1) to 0.93 (0.37) g in the dobutamine group (+0.64 g, 95% CI 0.37 to 0.91 g; p < 0.01). CONCLUSIONS: Using precordial leads this method offers potential for diagnostic application in the short term monitoring of myocardial function. PEA monitoring is feasible during pharmacological stress and documents left ventricular inotropic response quantitatively in a non-invasive and operator independent fashion.

Acceleration↗
PubMed2000

Peak endocardial acceleration reflects heart contractility also in atrial fibrillation.

Previous studies demonstrated that peak endocardial acceleration (PEA) in sinus rhythm is related to LV dP/dtmax. Until now, PEA was never evaluated during R-R interval variations in AF. The aim of this study was to establish the behavior of PEA in AF and the relationship of PEA versus LV dP/dtmax. Six sheep (65 +/- 6 kg) were instrumented with a LV Millar catheter and with an accelerometer lead. AF was induced and PEA, LV dP/dtmax, and ECG were monitored. AF persisted for 5 +/- 1.3 minutes. From sinus rhythm to AF, the heart rate went from 92 +/- 3 to 130 +/- 35 beats/min (P < 0.05), LV dP/dtmax from 684 +/- 18 to 956 +/- 344 mmHg/s (P = NS) and PEA from 0.82 +/- 0.06 to 0.94 +/- 0.33 g (P = NS). The correlation between PEA and LV dP/dtmax was significative in sinus rhythm (r = 0.7, P < 0.05) and in AF (r = 0.8, P < 0.05). A positive relationship was found between the preceding interval and PEA (r = 0.4 +/- 0.07, P < 0.05) and LV dP/dtmax (r = 0.61 +/- 0.08, P < 0.05), while a negative one was found between the prepreceding interval and both PEA (r = -0.39 +/- 0.11, P < 0.05) and LV dP/dtmax (r = -0.64 +/- 0.05, P < 0.05). At the onset of AF, LV dP/dtmax and PEA showed similar changes: beat-to-beat correlation between PEA and LV dP/dtmax was high. As for LV dP/dtmax, PEA is positively related to the preceding interval and negatively related to the prepreceding interval. These data confirm that PEA reflects heart contractility also during AF and hold promise for the use of this sensor in therapeutic implantable devices.

Animals↗
PubMed1997

Detecting incipient vasovagal syncope: intraventricular acceleration.

The peak endocardial acceleration (PEA) caused by ventricular isometric contraction can be measured with an implantable microaccelerometer located inside the tip of a normal unipolar pacing lead. It has been shown that PEA correlates with myocardial contractility and the maximum rate of rise of ventricular pressure (peak dP/dt) of the left ventricle. A PEA measuring system was temporarily inserted into the apex of the right ventricle in seven patients affected by syncope of uncertain origin. Each patient subsequently underwent 60 degrees tilt testing with three different protocols: without pharmacological challenge (baseline); potentiated with sublingual trinitroglycerin (at a dose of 0.3 mg); and with isoproterenol infusion (at a dose of 3 micrograms/min). Each phase lasted 20 minutes. Syncope was induced in 1 patient during the baseline phase, in 3 patients during the trinitrin phase, and in 4 patients during the isoproterenol phase. Six patients had a negative response during the baseline phase and served as a control group. From the beginning of upright posture to the time of maximum heart rate, PEA increased by about the same amount in both positive and negative patients, but absolute values were from two- to three fold higher with isoproterenol (from 1.2 +/- 0.5 G to 1.6 +/- 0.8 G, from 0.8 +/- 0.2 G to 1.2 +/- 0.4 G, and from 2.8 +/- 1.8 G to 3.6 +/- 1.8 G, respectively, for negative, positive baseline or trinitrin, and positive isoproterenol tests). At the time of syncope, PEA values fell to baseline values. PEA changes were inversely correlated with blood pressure changes and directly correlated with heart rate changes. Thus, tilt induced syncope occurred both at low and high levels of left ventricular contractility. Whether spontaneous syncopes occur at low or high PEA behavior remains to be established. Since heart rate correlates well with changes in PEA and is far easier to measure, it is unlikely that a PEA measurement system or, in general, a contractility-based system, might become an ideal sensing parameter for the introduction of devices to combat vasovagal syncope.

Acceleration↗
PubMed1996

An implantable intracardiac accelerometer for monitoring myocardial contractility. The Multicenter PEA Study Group.

As the myocardium contracts isometrically, it generates vibrations that are transmitted throughout the heart. These vibrations can be measured with an implantable microaccelerometer located inside the tip of an otherwise conventional unipolar pacing lead. These vibrations are, in their audible component, responsible for the first heart sound. The aim of this study was to evaluate, in man, the clinical feasibility and reliability of intracavity sampling of Peak Endocardial Acceleration (PEA) of the first heart sound vibrations using an implantable tip mounted accelerometer. We used a unidirectional accelerometer located inside the stimulating tip of a standard unipolar pacing lead: the sensor has a frequency response of DC to 1 kHz and a sensitivity of 5 mV/G (G = 9.81 m/s-2). The lead was connected to an external signal amplifier with a frequency range of 0.05-1,000 Hz and to a peak-to-peak detector synchronized with the endocardial R wave scanning the isovolumetric contraction phase. Following standard electrophysiological studies, sensor equipped leads were temporarily inserted in the RV of 15 patients (68 +/- 15 years), with normal regional and global ventricular function, to record PEA at rest, during AAI pacing, during VVI pacing, and during dobutamine infusion (up to 20 micrograms/kg per min). PEA at baseline was 1.1 G +/- 0.5 (heart rate = 75 +/- 14 beats/min) and increased to 1.3 G +/- 0.9 (P = NS vs baseline) during AAI pacing (heart rate = 140 beats/min) and to 1.4 G +/- 0.5 (P = NS vs baseline) during VVI pacing (heart rate = 140 beats/min). Dobutamine infusion increased PEA to 3.7 G +/- 1.1 (P < 0.001 vs baseline), with a heart rate of 121 +/- 13 beats/min. In a subset of three patients, simultaneous hemodynamic RV monitoring was performed to obtain RV dP/dtmax, whose changes during dobutamine and pacing were linearly related to changes in PEA (r = 0.9; P < 0.001). In conclusion, the PEA recording can be consistently and safely obtained with an implantable device. Pharmacological inotropic stimulation, but not pacing induced chronotropic stimulation, increases PEA amplitude, in keeping with experimental studies, suggesting that PEA is an index of myocardial contractility. Acute variations in PEA are closely paralleled by changes in RV dP/dtmax, but are mainly determined by LV events. The clinical applicability of the method using RV endocardial leads and an implantable device offers potential for diagnostic applications in the long-term monitoring of myocardial function in man.

Acceleration↗
PubMed1985

Respiration-dependent ventricular pacing compared with fixed ventricular and atrial-ventricular synchronous pacing: aerobic and hemodynamic variables.

A pacemaker that adapts heart rate in response to the patient's metabolic requirements has been developed. The pacemaker uses breathing frequency and tidal volume as the indicators of physiologic demand. Maximal physical work capacity, anaerobic threshold, oxygen uptake (16 patients) and hemodynamic variables (9 patients) were assessed with fixed rate (VVI), atrial synchronous (VDT/I) and respiration-dependent ventricular (VVI-RD) pacing. All subjects attained their anaerobic threshold in stress tests with VVI pacing. The maximal physical capacity (p less than 0.001), work time to attain the anaerobic threshold (p less than 0.01) and oxygen uptake (p less than 0.001) were significantly greater with VVI-RD than with VVI pacing. The transition from the supine to the standing position was characterized by a significant increase of cardiac index at rest with both VDT/I and VVI-RD pacing as compared with VVI pacing. Progressive increments in the cardiac index and average left ventricular stroke work index were significantly different at submaximal and maximal exercise when VVI and VVI-RD were compared. At maximal exercise, mean cardiac output was also significantly different: 10.21 +/- 2.5 (SD) liters/min with VVI, 11.2 +/- 0.8 liters/min with VDT/I (p less than 0.05) and 12.65 +/- 3.1 liters/min with VVI-RD (p less than 0.05) pacing. Maximal oxygen extraction values were greater with VVI and VVI-RD pacing than with VDT/I pacing. Pulmonary artery end-diastolic pressures at maximal exercise were within the normal range with the three different modes of pacing. In conclusion, there is a significant (25%) improvement in exercise performance with VVI-RD pacing as compared with VVI pacing.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1984

Increasing cardiac rate by tracking the respiratory rate.

The rate responsive pacemaker using respiratory rate as a sensor was implanted in 22 patients, 19 patients for ventricular pacing and three for atrial pacing. The level of exercise achieved with this system was consistently higher than with a fixed ventricular pacing rate. In addition, no special chemical or mechanical sensors are required; the sensor itself is simple, long-lasting, and energy efficient. Thus, this system adapts easily to the individual patient.

Adolescent↗
PubMed1984

Respiration as a reliable physiological sensor for controlling cardiac pacing rate.

A study was carried out to determine whether variations in the respiration rate during physical exercise could be used as a physiological variable in controlling the rate of an implanted pacemaker. The relation between respiration rate and heart rate was significantly correlated in 73 patients (19 with normal lung function, four with restrictive pulmonary disease, and 50 with obstructive airways disease) during repeated calibrated ergometric tests; no significant differences were found between the subgroups. An external computerised programmable system with algorithm control activated by a radio frequency system was used to vary the cardiac stimulation rate in relation to respiration rate in 11 patients implanted with ventricular inhibited pacemakers. In addition, a prototype programmable pacemaker dependent on respiration rate was implanted in two patients. Maximum values of oxygen uptake, minute ventilation, and work time were increased during the exercise stress tests when the variable cardiac pacing rate was used. Thus respiration rate appears to be a valid and stable physiological variable for controlling the cardiac stimulation rate in order to improve cardiac output in patients dependent on pacemakers.

Aged↗
PubMed1983

Respiratory rate as a determinant of optimal pacing rate.

Efforts have been made to utilize biologic parameters for determining optimal cardiac pacing rates. In this study of 67 patients, a significant relationship between heart rate and respiratory rate was observed during dynamic exercise. A system using a radiofrequency activator to modify pacing rate is described. Eleven patients have received VVI pacemakers with a similar implanted radio receiver coil. In two patients the fully automatic system has been successfully implanted. The experience with respiratory rate as a determinant of pacing rate is encouraging.

Aged↗
PubMed1982

Study of the hemocoagulative parameters in hemoperfusion on polymer coated resins.

A hemoperfusion column containing anionic exchange resin coated with a new polymer has been tested in vivo for blood compatibility. The hemocoagulative parameters, evaluated before and after the cartridge during hemoperfusion, did not show any significant alteration even as regards the number and the functionality of the platelets nor as regards a possible activation of the fibrinolysis process. On the basis of these results, the hemoperfusion system examined can be regarded as hemocompatible from the hemocoagulative standpoint.

Anion Exchange Resins↗
PubMed1976

An evaluation of echography in the diagnosis of pancreatic disease.

In the present study an attempt to evaluate the efficacy of echography as a diagnostic tool has been made. A total of 52 patients (chronic pancreatitis (42); pancreatic cysts (three); and carcinoma of the pancreas (seven)) were studied and the results compared with those from other diagnostic techniques. In 65.7% of chronic pancreatitis patients, and in all cases of carcinoma of the pancreas, echography provided evidence of pancreatic abnormality but in no case could an unambiguous diagnosis of the disease be made. However, in all cases of pancreatic cyst, echography gave precise and unequivocal diagnostic information. There was good agreement between the echographic picture and surgical findings. Cholangiography and duodenography indicated duodenal and choledochal compression in a high proportion of cases in which echography revealed enlargement of the head of the pancreas. It is concluded that echography is a simple, safe, and valuable addition to the techniques available for studying the pancreas.

Adolescent↗